EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Treatment strategies for cisplatin-ineligible metastatic bladder cancer: Emerging therapies and future perspectives

Kyung Hwan Kim iD, Do Thanh Truc Phan iD, Hong Koo Ha iD, Eui Hyun Jung iD, Geehyun Song iD, Ho Kyung Seo iD

Investigative and Clinical Urology · 2025 · 66 (6) · 471

DOI: 10.4111/icu.20250316 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Investigative and Clinical Urology, 2025. Verfasst von Kyung Hwan Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, the combination of enfortumab vedotin and pembrolizumab has been recommended as the preferred first-line therapy for metastatic or locally advanced urothelial carcinoma owing to its substantial survival benefits. However, its high-cost limits accessibility, leading to many patients receiving cisplatin-based chemotherapy as a more practical alternative. Therefore, cisplatin-based combination chemotherapy remains a widely used first-line treatment for metastatic bladder cancer (MBC). Nonetheless, nearly half of the patients are ineligible for cisplatin owing to factors such as renal impairment, poor performance status, or other comorbidities. The definition of cisplatin ineligibility, which is often based on the Galsky criteria, lacks robust scientific validation, and limited pharmacokinetic data on the effects of cisplatin in patients with renal impairment are available. This review explored alternative treatment strategies for cisplatin-ineligible patients, including immune checkpoint inhibitors, carboplatin-based regimens, antibody-drug conjugates, and novel combination therapies. Notably, recent advancements, such as the combination of enfortumab vedotin and pembrolizumab, have shown promising survival benefits in this patient population. Additionally, emerging targeted therapies, such as fibroblast growth factor receptor inhibitors, are reshaping the treatment landscape of cisplatin-ineligible patients with MBC, emphasizing the need for personalized approaches that balance efficacy and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellHumansCisplatinNeoplasm MetastasisAntineoplastic AgentsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

CisplatinDrug therapy, combinationImmune checkpoint inhibitorsImmunoconjugatesUrinary bladder neoplasms

Substanzen

CisplatinAntineoplastic AgentspembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
  • Department of Urology, Nhan Dan Gia Dinh Hospital, Hochiminh City, Vietnam.
  • Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea.
  • Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. seohk@ncc.re.kr.

ORCID-Profile: Kyung Hwan Kim, Do Thanh Truc Phan, Hong Koo Ha, Eui Hyun Jung, Geehyun Song, Ho Kyung Seo

Förderung

  • National Cancer Center

Zitieren

APA

Kim, K. H., Phan, D. T. T., Ha, H. K., Jung, E. H., Song, G., & Seo, H. K. (2025). Treatment strategies for cisplatin-ineligible metastatic bladder cancer: Emerging therapies and future perspectives. Investigative and Clinical Urology, 66(6), 471. https://doi.org/10.4111/icu.20250316

Vancouver

Kim KH, Phan DTT, Ha HK, Jung EH, Song G, Seo HK. Treatment strategies for cisplatin-ineligible metastatic bladder cancer: Emerging therapies and future perspectives. Investigative and Clinical Urology. 2025;66(6):471. doi:10.4111/icu.20250316

BibTeX
@article{Kim2025,
  author = {Kim, Kyung Hwan and Phan, Do Thanh Truc and Ha, Hong Koo and Jung, Eui Hyun and Song, Geehyun and Seo, Ho Kyung},
  title = {Treatment strategies for cisplatin-ineligible metastatic bladder cancer: Emerging therapies and future perspectives},
  journal = {Investigative and Clinical Urology},
  year = {2025},
  volume = {66},
  number = {6},
  pages = {471},
  doi = {10.4111/icu.20250316}
}
Kostenlos starten →